Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem

Replidyne, Inc., Louisville, Colorado 80027; Department of Pathology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio 44106; Clinical Microbiology Institute, Wilsonville, Oregon 97070; and Replidyne, Inc., Milford, Connecticut 06460

^* To whom correspondence should be addressed. Email: icritchley{at}replidyne.com.

	Abstract

Of 393 isolates of Streptococcus pneumoniae from U.S. children in 2005-2006, non-vaccine serotypes accounted for 89.1% of isolates, with serotype 19A the most prevalent, representing 30.5% of all isolates. MIC₉₀ of faropenem against serotype 19A isolates was 1 µg/ml, compared to 8 µg/ml against amoxicillin/clavulanate, cefdinir, cefuroxime axetil and azithromycin.